The Lancet November 23, 2002

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

James Shepherd, Gerard J Blauw, Michael B Murphy, et al.

Bottom Line

Pravastatin reduces the risk of coronary events, though not stroke or cognitive decline, in elderly individuals at high risk of or with existing vascular disease.

Key Findings

1. Pravastatin significantly reduced the primary composite endpoint of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke compared to placebo (14.1% vs 16.2%; HR 0.85, 95% CI 0.74-0.97, p=0.014).

2. The primary benefit was driven by a reduction in coronary death and non-fatal myocardial infarction (HR 0.81, 95% CI 0.69-0.94, p=0.006), with coronary mortality specifically falling by 24% (p=0.043).

3. Stroke risk was unaffected by pravastatin therapy (HR 1.03, 95% CI 0.81-1.31, p=0.8).

4. Pravastatin did not significantly slow cognitive decline or decrease disability over the follow-up period.

5. New cancer diagnoses were higher in the pravastatin group (HR 1.25, 95% CI 1.04-1.51, p=0.020); however, an accompanying meta-analysis of all pravastatin and statin trials suggested this was a chance finding rather than a true adverse effect.

Study Design

Design

RCT

Double-Blind

Sample

5,804

Patients

Duration

3.2 yr

Median

Setting

Multicenter, Europe

Population Men and women aged 70-82 years with either preexisting vascular disease (coronary, cerebral, peripheral) or high risk factors for vascular disease, and a baseline total cholesterol of 4.0-9.0 mmol/L.

Intervention Pravastatin 40 mg orally once daily

Comparator Matching placebo

Outcome Composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke

Study Limitations

• The mean follow-up of 3.2 years was relatively short for a prevention trial, which may explain the lack of observed benefit regarding stroke prevention and cognitive decline.

• The trial included a mix of primary and secondary prevention patients; while the overall benefit was clear, the absolute benefit was smaller in the primary prevention subgroup.

• There was no significant reduction in all-cause mortality (10.3% pravastatin vs. 10.5% placebo), largely due to the advanced age of the cohort and competing risks from non-cardiovascular deaths.

• The unexpected increase in incident cancer diagnoses in the treatment arm clouded the initial safety profile, requiring additional meta-analyses to alleviate concerns.

Clinical Significance

PROSPER proved that statin therapy effectively decreases coronary risk in older populations (age >70). It challenged the prevailing clinical reluctance to prescribe lipid-lowering drugs to the elderly, firmly establishing that chronological age alone should not disqualify high-risk individuals from statin-mediated cardiovascular prevention.

Historical Context

Prior to PROSPER, landmark statin trials such as 4S, WOSCOPS, and CARE predominantly enrolled middle-aged individuals, leaving a substantial gap in evidence regarding the efficacy and safety of statins in patients over 70. Because older adults have high rates of competing non-cardiovascular mortality, it was widely debated whether lipid-lowering survival benefits seen in younger cohorts would translate to the elderly. PROSPER was the first large-scale prospective trial exclusively dedicated to this older age group, shifting paradigm norms and informing modern geriatric cardiology guidelines.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Pravastatin competitively inhibits HMG-CoA reductase. How does this mechanism lead to a reduction in coronary events, and what are the major adverse effects to monitor specifically when prescribing this class of drugs to elderly patients?

Key Response

This tests foundational knowledge of the statin mechanism of action, including the compensatory upregulation of hepatic LDL receptors, as well as high-yield side effects like myopathy and transaminitis that are highly relevant in older adults due to age-related pharmacokinetic changes and polypharmacy.

Resident

The PROSPER trial included both primary and secondary prevention cohorts of elderly patients. Given the study's findings, how do you practically approach the shared decision-making process for initiating a statin in an 80-year-old for primary prevention versus secondary prevention?

Key Response

Residents must learn to weigh the established absolute risk reduction of statins in secondary prevention against the more debated, modest benefits in primary prevention for the elderly, taking into account the patient's life expectancy, baseline risk, and time-to-benefit.

Fellow

PROSPER demonstrated a reduction in coronary events but no significant reduction in stroke or cognitive decline. How do differences in the pathophysiology of stroke in the elderly, such as cardioembolic or amyloid-related etiologies, explain this discrepancy compared to statin trials in younger atherosclerotic populations?

Key Response

Fellows should recognize that while statins stabilize atherosclerotic plaque, strokes in the very elderly often stem from non-atherosclerotic sources like atrial fibrillation or cerebral amyloid angiopathy, which are unaffected by LDL reduction, explaining the lack of benefit in this specific outcome.

Attending

A highly debated secondary finding in PROSPER was a slight increase in incident cancer in the pravastatin group. How do you use this historical finding to teach learners about contextualizing unexpected trial safety signals and the dangers of multiple hypothesis testing?

Key Response

Attendings must guide learners in the critical appraisal of unexpected secondary outcomes, demonstrating how Type I errors occur due to multiple testing and reinforcing how subsequent meta-analyses ultimately disproved the statin-cancer link, thereby teaching responsible interpretation of trial data.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The PROSPER trial utilized a composite primary endpoint of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Given that the stroke component showed no benefit, what are the methodological and statistical perils of using composite endpoints when an intervention affects the components heterogeneously?

Key Response

This challenges researchers to critique the use of composite endpoints, which can dilute the overall effect size and mislead clinical interpretation if the treatment effect is driven entirely by one component while another remains unaffected or trends in the opposite direction.

Journal Editor

If reviewing the PROSPER manuscript today, how would you evaluate the investigators' handling of the competing risk of non-cardiovascular mortality, given that a population aged 70-82 has a naturally high baseline rate of death from non-vascular causes?

Key Response

A seasoned reviewer would flag that in elderly cohorts, high rates of non-cardiovascular death represent competing risks that can artificially alter the Kaplan-Meier estimates for cardiovascular endpoints, necessitating specific statistical models like the Fine-Gray subdistribution hazard model for accurate outcome reporting.

Guideline Committee

Current ACC/AHA guidelines provide a Class IIb recommendation for initiating statins for primary prevention in adults over 75. How does the mixed primary and secondary prevention design of PROSPER complicate its use as foundational evidence for primary prevention guidelines in the elderly?

Key Response

Guideline committees must untangle the fact that PROSPER's overall positive result was heavily driven by the secondary prevention subgroup. Extrapolating these mixed results to justify primary prevention in the very elderly requires careful nuance, which is reflected in the current weaker Class IIb guideline recommendation.

Clinical Landscape

Noteworthy Related Trials

2002

Heart Protection Study (HPS)

n = 20,536 · Lancet

Tested

Simvastatin 40 mg daily

Population

Adults aged 40-80 years with high risk of coronary heart disease

Comparator

Placebo

Endpoint

All-cause mortality and major vascular events

Key result: Simvastatin significantly reduced all-cause mortality, coronary death, and major vascular events regardless of baseline cholesterol levels.

2002

ALLHAT-LLT

n = 10,355 · JAMA

Tested

Pravastatin 40 mg daily

Population

Ambulatory adults aged 55 years and older with hypertension and moderate hypercholesterolemia

Comparator

Usual care

Endpoint

All-cause mortality

Key result: Pravastatin did not significantly reduce all-cause mortality or CHD events compared to usual care in this specific trial, partly due to high out-of-study statin use in the usual care group.

2008

JUPITER Trial

n = 17,802 · NEJM

Tested

Rosuvastatin 20 mg daily

Population

Healthy men aged 50+ and women aged 60+ with normal LDL-C but elevated hsCRP

Comparator

Placebo

Endpoint

First major cardiovascular event

Key result: Rosuvastatin significantly reduced the incidence of major cardiovascular events in apparently healthy older individuals with elevated hsCRP.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis